NYSEAMERICAN:TOVX Theriva Biologics Q3 2025 Earnings Report $0.23 0.00 (0.00%) Closing price 09/18/2026 04:10 PM EasternExtended Trading$0.24 +0.00 (+1.50%) As of 08:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Theriva Biologics EPS ResultsActual EPS-$0.45Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATheriva Biologics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATheriva Biologics Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Theriva Biologics Earnings HeadlinesTheriva Biologics Inc.August 12, 2026 | marketwatch.comTheriva Biologics Inc.August 12, 2026 | marketwatch.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 21 at 1:00 AM | Porter & Company (Ad)Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial ResultsAugust 12, 2026 | markets.businessinsider.comTheriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del segundo trimestre de 2026August 11, 2026 | globenewswire.comTheriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line ...August 6, 2026 | finance.yahoo.comSee More Theriva Biologics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Theriva Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Theriva Biologics and other key companies, straight to your email. Email Address About Theriva BiologicsTheriva Biologics (NYSEAMERICAN:TOVX) is a clinical-stage biotechnology company focused on developing treatments that use microbiome-based technologies and targeted biological approaches to address serious diseases. The company’s portfolio includes investigational therapies for oncology and gastrointestinal conditions. Its lead oncology program, VCN-01, is a genetically modified oncolytic adenovirus designed to selectively replicate in tumor cells and stimulate an immune response against cancer. Theriva has studied VCN-01 in combination with chemotherapy for pancreatic ductal adenocarcinoma. The company’s microbiome-focused programs include SYN-004 (ribaxamase), an oral enzyme intended to protect the gut microbiome during treatment with certain intravenous antibiotics, and SYN-020, an investigational intestinal alkaline phosphatase therapy for gastrointestinal and related conditions. The company was formerly known as AzurRx BioPharma, Inc. and adopted the name Theriva Biologics following its expansion into oncology through the acquisition of VCN Biosciences. Its drug candidates remain investigational and are being developed through clinical research rather than marketed as approved commercial products.View Theriva Biologics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing3 Software Stocks Rebounding as AI Fears Give Way to GrowthThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big Move Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
